The American Heart Association and the American College of Cardiology joint guideline addressing cardiovascular evaluation ...

The American Heart Association and the American College of Cardiology joint guideline addressing cardiovascular evaluation ...

SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.

Recurrent stroke risk was lower among patients with type 2 diabetes who used SGLT2 inhibitors within 3 months of ischemic stroke.

Canada: Recent post hoc analyses from the VERTIS CV trial reveal promising results for ertugliflozin, a medication used to ...

New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.

SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, ...

In patients with type 2 diabetes, GLP-1 receptor agonists and SGLT2 inhibitors have similar kidney and cardiovascular outcomes. Similar kidney and cardiovascular outcomes are found with glucagon-like ...

A class of drugs used to treat diabetes has been linked to a 20% lower risk of dementia and Parkinson's disease. | ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

When surveyed, many physicians said the belief that patients had adequate symptom control was why they didn’t add more meds.

Diabetes medications, specifically sodium-glucose cotransporter-2 (SGLT2) inhibitors, may be linked to a decreased risk of ...